Camurus AB (OTCPK:CAMRF)
$ 58.22 0 (0%) Market Cap: 3.26 Bil Enterprise Value: 3.04 Bil PE Ratio: 80.53 PB Ratio: 13.45 GF Score: 75/100

Q2 2022 Camurus AB Earnings Call Transcript

Jul 15, 2022 / 12:00PM GMT
Release Date Price: $12.9
Operator

Good day, and welcome to the Camurus Q2 2022 Earnings Conference Call. (Operator Instructions) Please note, this event is being recorded.

I would now like to turn the conference over to Fredrik Tiberg. Please go ahead.

Fredrik Tiberg;publ;CEO
Camurus AB;President & Director

()- -

Thank you so much, and hello, everybody. Thank you for taking the time to joining us this Friday afternoon for our second quarter earnings call. It's a pleasure to update you on the continued progress of Camurus.

Please note our forward-looking statements. And this is today's agenda. With me on the call is Jon Garay, our Chief Financial Officer; and on the phone from Cambridge, U.K., is Richard Jameson, our Chief Commercial Officer.

Before going to highlights, here is a snapshot of Camurus 3 years after the approval and launch of our first transformative medicine, Buvidal. We have gone far proven our commercial execution ability and emerged as a leader in the opioid dependence treatment field, advanced our late

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot